CD300ld was competitively blocked by the injection of CD300ld extracellular domain protein, presenting similarly to CD300ld deletion, and showed meaningful anti‐tumor cooperation with anti‐PD1, implying the potential of CD300ld to be a therapeutic target. Here, CD300LD is linked to neoplasm.